Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2014 08:00 ET | Source: AV Therapeutics, Inc.

AV Therapeutics Successfully Completes GMP Synthesis of Its Lead Prostate Cancer Chemotherapeutic Drug, Capridine

NEW YORK, Nov. 24, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, is pleased to announce the...
May 07, 2014 09:02 ET | Source: AV Therapeutics, Inc.

Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug

NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief,...
February 05, 2014 07:00 ET | Source: AV Therapeutics, Inc.

AV Therapeutics Announces Collaboration With DavosPharma to Manufacture Chemotherapeutic Drug Capridine

NEW YORK, Feb. 5, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc., ("AV Therapeutics" or "the Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, today announced that it has...
January 22, 2014 11:27 ET | Source: AV Therapeutics, Inc.

AV Therapeutics Announces Information Available Through S&P's Corporation Records Program

NEW YORK, Jan. 22, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced that its company...
January 02, 2014 07:00 ET | Source: AV Therapeutics, Inc.

AV Therapeutics Begins Trading on the OTCQB Under the Symbol "AVTH"

NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced that its common stock...